Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".
作者信息
Messori Andrea, Peyvandi Flora, Trippoli Sabrina, Palla Roberta, Rosendaal Frits R, Mannucci Pier Mannuccio
机构信息
HTA Unit, ESTAR, Regional Health Service, Florence, Italy.
"A. Bianchi Bonomi" Haemophilia and Thrombosis Centre, "Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico" and Luigi Villa" Foundation, Milan, Italy.
出版信息
Blood Transfus. 2019 Jan;17(1):86. doi: 10.2450/2017.0253-17. Epub 2017 Dec 22.
Abstract
摘要
相似文献
1
Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".
Blood Transfus. 2019 Jan;17(1):86. doi: 10.2450/2017.0253-17. Epub 2017 Dec 22.
2
Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.
Blood Transfus. 2019 Jan;17(1):85. doi: 10.2450/2017.0160-17. Epub 2017 Oct 3.
3
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.
Blood Transfus. 2018 Feb;16(2):215-220. doi: 10.2450/2017.0352-16. Epub 2017 May 15.
4
Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies.
Haemophilia. 2017 Mar;23(2):e87-e92. doi: 10.1111/hae.13193. Epub 2017 Feb 20.
5
Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.
Thromb Haemost. 2015 Jul;114(1):56-64. doi: 10.1160/TH14-10-0882. Epub 2015 May 28.
6
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Haemophilia. 2019 May;25(3):398-407. doi: 10.1111/hae.13747. Epub 2019 May 7.
7
Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate : Final report from a prospective study.
Haemophilia. 2018 Mar;24(2):221-228. doi: 10.1111/hae.13385. Epub 2018 Jan 3.
8
Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
Haemophilia. 1999 May;5(3):145-54. doi: 10.1046/j.1365-2516.1999.00300.x.
9
Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
Haemophilia. 2018 Mar;24(2):245-252. doi: 10.1111/hae.13413. Epub 2018 Feb 13.
10
High-titre factor VIII inhibitor in two children with mild haemophilia A.
Haemophilia. 2001 Mar;7(2):215-9. doi: 10.1046/j.1365-2516.2001.00493.x.
本文引用的文献
1
Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.
Blood Transfus. 2019 Jan;17(1):85. doi: 10.2450/2017.0160-17. Epub 2017 Oct 3.
2
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.
Blood Transfus. 2018 Feb;16(2):215-220. doi: 10.2450/2017.0352-16. Epub 2017 May 15.
3
Impact of inhibitors on hemophilia A mortality in the United States.
Am J Hematol. 2015 May;90(5):400-5. doi: 10.1002/ajh.23957. Epub 2015 Feb 5.
Zotero 插件